BIOMAT Database Logo BIOMAT Database Logo

Molecular Docking, Computational, and Antithrombotic Studies of Novel 1,3,4-Oxadiazole Derivatives. 2018

Majda Batool, and Affifa Tajammal, and Firdous Farhat, and Francis Verpoort, and Zafar A K Khattak, and , and Muhammad Shahid, and Hafiz Adnan Ahmad, and Munawar Ali Munawar, and Muhammad Zia-Ur-Rehman, and Muhammad Asim Raza Basra
Institute of Chemistry, University of the Punjab, New Campus, Lahore 54590, Pakistan. majdabatool12@gmail.com.

A new series of 1,3,4-oxadiazoles derivatives was synthesized, characterized, and evaluated for their in vitro and in vivo anti-thrombotic activity. Compounds (3a⁻3i) exhibited significant clot lysis with respect to reference drug streptokinase (30,000 IU), and enhanced clotting time (CT) values (130⁻342 s) than heparin (110 s). High affinity towards 1NFY with greater docking score was observed for the compounds (3a, 3i, 3e, 3d, and 3h) than the control ligand RPR200095. In addition, impressive inhibitory potential against factor Xa (F-Xa) was observed with higher docking scores (5612⁻6270) with Atomic Contact Energy (ACE) values (-189.68 to -352.28 kcal/mol) than the control ligand RPR200095 (Docking score 5192; ACE -197.81 kcal/mol). In vitro, in vivo, and in silico results proposed that these newly synthesized compounds might be used as anticoagulant agents.

UI MeSH Term Description Entries
D008297 Male Males
D010069 Oxadiazoles Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms. Oxadiazole
D005343 Fibrinolytic Agents Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats

Related Publications

Majda Batool, and Affifa Tajammal, and Firdous Farhat, and Francis Verpoort, and Zafar A K Khattak, and , and Muhammad Shahid, and Hafiz Adnan Ahmad, and Munawar Ali Munawar, and Muhammad Zia-Ur-Rehman, and Muhammad Asim Raza Basra
Synthesis, anticholinesterase activity, molecular docking, and molecular dynamic simulation studies of 1,3,4-oxadiazole derivatives.
November 2022, Archiv der Pharmazie,
Majda Batool, and Affifa Tajammal, and Firdous Farhat, and Francis Verpoort, and Zafar A K Khattak, and , and Muhammad Shahid, and Hafiz Adnan Ahmad, and Munawar Ali Munawar, and Muhammad Zia-Ur-Rehman, and Muhammad Asim Raza Basra
Synthesis, urease inhibition, antioxidant, antibacterial, and molecular docking studies of 1,3,4-oxadiazole derivatives.
January 2012, ISRN pharmacology,
Majda Batool, and Affifa Tajammal, and Firdous Farhat, and Francis Verpoort, and Zafar A K Khattak, and , and Muhammad Shahid, and Hafiz Adnan Ahmad, and Munawar Ali Munawar, and Muhammad Zia-Ur-Rehman, and Muhammad Asim Raza Basra
Synthesis, carbonic anhydrase inhibition, anticancer activity, and molecular docking studies of 1,3,4-oxadiazole derivatives.
February 2023, Molecular diversity,
Majda Batool, and Affifa Tajammal, and Firdous Farhat, and Francis Verpoort, and Zafar A K Khattak, and , and Muhammad Shahid, and Hafiz Adnan Ahmad, and Munawar Ali Munawar, and Muhammad Zia-Ur-Rehman, and Muhammad Asim Raza Basra
Biological Evaluation and Molecular Docking Studies of Novel 1,3,4-Oxadiazole Derivatives of 4,6-Dimethyl-2-sulfanylpyridine-3-carboxamide.
January 2022, International journal of molecular sciences,
Majda Batool, and Affifa Tajammal, and Firdous Farhat, and Francis Verpoort, and Zafar A K Khattak, and , and Muhammad Shahid, and Hafiz Adnan Ahmad, and Munawar Ali Munawar, and Muhammad Zia-Ur-Rehman, and Muhammad Asim Raza Basra
1,3,4-oxadiazole derivatives: synthesis, characterization, antimicrobial potential, and computational studies.
January 2014, BioMed research international,
Majda Batool, and Affifa Tajammal, and Firdous Farhat, and Francis Verpoort, and Zafar A K Khattak, and , and Muhammad Shahid, and Hafiz Adnan Ahmad, and Munawar Ali Munawar, and Muhammad Zia-Ur-Rehman, and Muhammad Asim Raza Basra
Synthesis, in Vitro Cholinesterase Inhibition, Molecular Docking, DFT, and ADME Studies of Novel 1,3,4-Oxadiazole-2-Thiol Derivatives.
August 2022, Chemistry & biodiversity,
Majda Batool, and Affifa Tajammal, and Firdous Farhat, and Francis Verpoort, and Zafar A K Khattak, and , and Muhammad Shahid, and Hafiz Adnan Ahmad, and Munawar Ali Munawar, and Muhammad Zia-Ur-Rehman, and Muhammad Asim Raza Basra
Design, synthesis, and molecular docking of novel 3,5-disubstituted-1,3,4-oxadiazole derivatives as iNOS inhibitors.
August 2021, Archiv der Pharmazie,
Majda Batool, and Affifa Tajammal, and Firdous Farhat, and Francis Verpoort, and Zafar A K Khattak, and , and Muhammad Shahid, and Hafiz Adnan Ahmad, and Munawar Ali Munawar, and Muhammad Zia-Ur-Rehman, and Muhammad Asim Raza Basra
Synthesis, biological evaluation and molecular docking studies of 1,3,4-oxadiazole derivatives as potential immunosuppressive agents.
May 2012, Bioorganic & medicinal chemistry,
Majda Batool, and Affifa Tajammal, and Firdous Farhat, and Francis Verpoort, and Zafar A K Khattak, and , and Muhammad Shahid, and Hafiz Adnan Ahmad, and Munawar Ali Munawar, and Muhammad Zia-Ur-Rehman, and Muhammad Asim Raza Basra
Synthesis, molecular docking study and anticancer activity of novel 1,3,4-oxadiazole derivatives as potential tubulin inhibitors.
February 2023, Heliyon,
Majda Batool, and Affifa Tajammal, and Firdous Farhat, and Francis Verpoort, and Zafar A K Khattak, and , and Muhammad Shahid, and Hafiz Adnan Ahmad, and Munawar Ali Munawar, and Muhammad Zia-Ur-Rehman, and Muhammad Asim Raza Basra
Design, synthesis, anticancer evaluation and molecular docking studies of 1,2,3-triazole incorporated 1,3,4-oxadiazole-Triazine derivatives.
May 2023, Heliyon,
Copied contents to your clipboard!